Get the Stockscreener App
25.19
0.88%
0.22
After Hours:
25.19
Bicara Therapeutics Inc stock is traded at $25.19, with a volume of 487.90K.
It is up +0.88% in the last 24 hours and up +0.12% over the past month.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
See More
Previous Close:
$24.97
Open:
$25.09
24h Volume:
487.90K
Relative Volume:
2.29
Market Cap:
$1.37B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+6.56%
1M Performance:
+0.12%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$24.31
$26.00
1-Week Range:
$22.55
$26.00
52-Week Range:
$18.33
$27.94
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Name
Bicara Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Bicara Therapeutics Inc Stock (BCAX) Latest News
Bicara Therapeutics stock gets Buy rating from H.C. Wainwright on asset - Investing.com
Bicara Therapeutics (NASDAQ:BCAX) Coverage Initiated at Rodman & Renshaw - MarketBeat
Biocon Stole Licensed Cancer Biotech to Fuel Spinoff, Suit Says - Bloomberg Law
Balance Sheet Breakdown: Bicara Therapeutics Inc. (BCAX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
In the Green: Bicara Therapeutics Inc. (BCAX) Closes at 19.00, Up/Down -6.40 from Previous Day - The Dwinnex
Down rounds don’t aid post-IPO performance - BioCentury
Bicara shares initiated with Buy on cancer drug potential By Investing.com - Investing.com South Africa
Bicara stock poised for growth with late-stage transition, Morgan Stanley optimistic - Investing.com
Bicara Therapeutics stock sees upside with lead drug potential, says Stifel - Investing.com
Bicara shares initiated with Buy on cancer drug potential - Investing.com India
Cantor Fitzgerald starts Bicara Therapeutics with Overweight rating - Investing.com
Cantor Fitzgerald starts Bicara Therapeutics with Overweight rating By Investing.com - Investing.com South Africa
Bicara Therapeutics stock sees upside with lead drug potential, says Stifel By Investing.com - Investing.com South Africa
Three startups aim to raise $400 mln as US biotech IPOs gain traction - Reuters
Bicara Leads Trio of US Biotech IPOs Raising $703 Million - MSN
Market Update: Bicara Therapeutics Inc. (BCAX) Sees Negative Movement, Closing at 24.43 - The Dwinnex
Bicara Therapeutics, Adecoagro, and More Stocks See Action From Activist Investors - MSN
Kiran Mazumdar-Shaw’s niece makes debut at Nasdaq as Bicara Therapeutics goes public - The Financial Express
With IPO, have the capital and resources for clinical studies: Bicara CEO - The Economic Times
Bicara Therapeutics Rings the Opening Bell - Nasdaq
Bicara Therapeutics Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Biotech IPO Shares Climb in Debuts After Deals Upsized - MSN
TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc - GuruFocus.com
James E. Flynn Buys 70,000 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) Stock - Defense World
Ra capital executives buy Bicara Therapeutics shares for $32.99m By Investing.com - Investing.com South Africa
Ra Capital Management, L.P. Purchases 1,833,000 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) Stock - Defense World
Ra capital executives buy Bicara Therapeutics shares for $32.99m - Investing.com India
FMR LLC Acquires New Stake in Bicara Therapeutics Inc - Yahoo Finance
Deerfield entities buy Bicara Therapeutics shares worth $1.26m By Investing.com - Investing.com Australia
Deerfield entities buy Bicara Therapeutics shares worth $1.26m - Investing.com
Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity - Yahoo Finance
Bicara Therapeutics raises $362 million in Nasdaq debut - The Pharma Letter
MBX, Zenas And Bicara IPOs Generate Big First Day Returns, But Will They Last? - Scrip
Bicara Therapeutics Announces Closing of $362 Million - GlobeNewswire
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - StockTitan
Bicara, MBX Bio lead gainers as biotech trio makes trading debut - MSN
TPG-backed Bicara Therapeutics shares surge 46% in stellar market debut - MSN
Biotech IPOs Surge on Debut: Upsized Deals Boost Shares for Drug Developers Tackling Autoimmune Diseases - Share Price India News
Trio of first-day pops may bode well for biotech IPO window - BioCentury
Bicara Therapeutics Opens at $26.25 , Upsized IPO Priced at $18 By Investing.com - Investing.com Canada
2 Life Sciences Cos. Start Trading After Raising $540M Total - Law360
Bicara Therapeutics Rises 39% in Debut on Nasdaq - MarketWatch
3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders - MedCity News
Shares of two Mass. biotech IPOs rise on first day of trading - The Business Journals
Bicara, MBX Bio lead gainers among biotech IPOs (NASDAQ:BCAX) - Seeking Alpha
Bicara Therapeutics Inc Stock (BCAX) Financials Data
There is no financial data for Bicara Therapeutics Inc (BCAX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Bicara Therapeutics Inc Stock (BCAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Flynn James E | Possible Members of 10% Group |
Sep 17 '24 |
Buy |
18.00 |
70,000 |
1,260,000 |
897,587 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):